Literature DB >> 27815373

Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.

Qingtong Wang1,2, Yongming Liu1,3, Qin Fu1,4, Bing Xu1, Yuan Zhang5, Sungjin Kim1, Ruensern Tan1, Federica Barbagallo1, Toni West1, Ethan Anderson6, Wei Wei2, E Dale Abel5, Yang K Xiang1,7.   

Abstract

BACKGROUND: Type 2 diabetes mellitus (DM) and obesity independently increase the risk of heart failure by incompletely understood mechanisms. We propose that hyperinsulinemia might promote adverse consequences in the hearts of subjects with type-2 DM and obesity.
METHODS: High-fat diet feeding was used to induce obesity and DM in wild-type mice or mice lacking β2-adrenergic receptor (β2AR) or β-arrestin2. Wild-type mice fed with high-fat diet were treated with a β-blocker carvedilol or a GRK2 (G-protein-coupled receptor kinase 2) inhibitor. We examined signaling and cardiac contractile function.
RESULTS: High-fat diet feeding selectively increases the expression of phosphodiesterase 4D (PDE4D) in mouse hearts, in concert with reduced protein kinase A phosphorylation of phospholamban, which contributes to systolic and diastolic dysfunction. The expression of PDE4D is also elevated in human hearts with DM. The induction of PDE4D expression is mediated by an insulin receptor, insulin receptor substrate, and GRK2 and β-arrestin2-dependent transactivation of a β2AR-extracellular regulated protein kinase signaling cascade. Thus, pharmacological inhibition of β2AR or GRK2, or genetic deletion of β2AR or β-arrestin2, all significantly attenuate insulin-induced phosphorylation of extracellular regulated protein kinase and PDE4D induction to prevent DM-related contractile dysfunction.
CONCLUSIONS: These studies elucidate a novel mechanism by which hyperinsulinemia contributes to heart failure by increasing PDE4D expression and identify β2AR or GRK2 as plausible therapeutic targets for preventing or treating heart failure in subjects with type 2 DM.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  diabetic cardiomyopathy; heart failure; insulin; phosphodiesterase; β-adrenergic receptors

Mesh:

Substances:

Year:  2016        PMID: 27815373      PMCID: PMC5302024          DOI: 10.1161/CIRCULATIONAHA.116.022281

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  50 in total

1.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

Authors:  Prakash C Deedwania; Thomas D Giles; Michael Klibaner; Jalal K Ghali; Johan Herlitz; Per Hildebrandt; John Kjekshus; Jindrich Spinar; Jiri Vitovec; Hilary Stanbrook; John Wikstrand
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

2.  Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

Authors:  Christian Torp-Pedersen; Marco Metra; Andrew Charlesworth; Phillip Spark; Mary Ann Lukas; Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Willem J Remme; Armin Scherhag
Journal:  Heart       Date:  2007-01-19       Impact factor: 5.994

3.  Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice.

Authors:  Pavan K Battiprolu; Berdymammet Hojayev; Nan Jiang; Zhao V Wang; Xiang Luo; Myriam Iglewski; John M Shelton; Robert D Gerard; Beverly A Rothermel; Thomas G Gillette; Sergio Lavandero; Joseph A Hill
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

Review 4.  Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

Authors:  Steven Joseph Haas; Theo Vos; Richard E Gilbert; Henry Krum
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

5.  Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases.

Authors:  Alessandra Ghigo; Alessia Perino; Hind Mehel; Alexandra Zahradníková; Fulvio Morello; Jérôme Leroy; Viacheslav O Nikolaev; Federico Damilano; James Cimino; Elisa De Luca; Wito Richter; Ruth Westenbroek; William A Catterall; Jin Zhang; Chen Yan; Marco Conti; Ana Maria Gomez; Grégoire Vandecasteele; Emilio Hirsch; Rodolphe Fischmeister
Journal:  Circulation       Date:  2012-09-24       Impact factor: 29.690

Review 6.  Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease?

Authors:  D S Bell
Journal:  Diabetes Care       Date:  1995-05       Impact factor: 19.112

Review 7.  Diabetic cardiomyopathy revisited.

Authors:  Sihem Boudina; E Dale Abel
Journal:  Circulation       Date:  2007-06-26       Impact factor: 29.690

8.  Primary myocardial disease in the diabetic mouse. An ultrastructural study.

Authors:  F Giacomelli; J Wiener
Journal:  Lab Invest       Date:  1979-04       Impact factor: 5.662

9.  Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction.

Authors:  Stuart A Cook; Anabel Varela-Carver; Marco Mongillo; Christina Kleinert; Muhammad T Khan; Lucia Leccisotti; Nicola Strickland; Takashi Matsui; Saumya Das; Anthony Rosenzweig; Prakash Punjabi; Paolo G Camici
Journal:  Eur Heart J       Date:  2009-10-01       Impact factor: 29.983

10.  Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38α MAPK during insulin resistance.

Authors:  Yajuan Qi; Zihui Xu; Qinglei Zhu; Candice Thomas; Rajesh Kumar; Hao Feng; David E Dostal; Morris F White; Kenneth M Baker; Shaodong Guo
Journal:  Diabetes       Date:  2013-11       Impact factor: 9.461

View more
  49 in total

1.  Postprandial Insulin Response and Clearance Among Black and White Women: The Federal Women's Study.

Authors:  Stephanie T Chung; Mirella Galvan-De La Cruz; Paola C Aldana; Lilian S Mabundo; Christopher W DuBose; Anthony U Onuzuruike; Mary Walter; Ahmed M Gharib; Amber B Courville; Arthur S Sherman; Anne E Sumner
Journal:  J Clin Endocrinol Metab       Date:  2019-01-01       Impact factor: 5.958

2.  A20 prevents obesity-induced development of cardiac dysfunction.

Authors:  Wenjing Xu; Cheng Wang; Minglu Liang; Long Chen; Qin Fu; Fengxiao Zhang; Yan Wang; Dan Huang; Kai Huang
Journal:  J Mol Med (Berl)       Date:  2017-11-16       Impact factor: 4.599

3.  Insulin-dependent metabolic and inotropic responses in the heart are modulated by hydrogen peroxide from NADPH-oxidase isoforms NOX2 and NOX4.

Authors:  Benjamin Steinhorn; Juliano L Sartoretto; Andrea Sorrentino; Natalia Romero; Hermann Kalwa; E Dale Abel; Thomas Michel
Journal:  Free Radic Biol Med       Date:  2017-09-14       Impact factor: 7.376

4.  Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent.

Authors:  Bat-Erdene Myagmar; James M Flynn; Patrick M Cowley; Philip M Swigart; Megan D Montgomery; Kevin Thai; Divya Nair; Rumita Gupta; David X Deng; Chihiro Hosoda; Simon Melov; Anthony J Baker; Paul C Simpson
Journal:  Circ Res       Date:  2017-02-20       Impact factor: 17.367

5.  GRK5 Controls SAP97-Dependent Cardiotoxic β1 Adrenergic Receptor-CaMKII Signaling in Heart Failure.

Authors:  Bing Xu; Minghui Li; Ying Wang; Meimi Zhao; Stefano Morotti; Qian Shi; Qingtong Wang; Federica Barbagallo; Jian-Peng Teoh; Gopireddy R Reddy; Elizabeth F Bayne; Yongming Liu; Ao Shen; Jose L Puglisi; Ying Ge; Ji Li; Eleonora Grandi; Madeline Nieves-Cintron; Yang K Xiang
Journal:  Circ Res       Date:  2020-06-08       Impact factor: 17.367

Review 6.  Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors.

Authors:  Qin Fu; Qian Shi; Toni M West; Yang K Xiang
Journal:  J Cardiovasc Pharmacol       Date:  2017-08       Impact factor: 3.105

Review 7.  Basic Mechanisms of Diabetic Heart Disease.

Authors:  Rebecca H Ritchie; E Dale Abel
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

8.  Metabolic effects of carvedilol through β-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts.

Authors:  Berna Güven; Zümra Kara; Arzu Onay-Beşikci
Journal:  Br J Pharmacol       Date:  2020-11-15       Impact factor: 8.739

Review 9.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

Review 10.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.